Earlier this month, Actavis plc. announced that the company had adopted Allergan plc (NYSE: AGN) as its new global name. This move marks a shift and refocus to world-renowned branded pharmaceuticals whilst providing unique opportunities to respond quickly to customers and provides patients around the globe with increased access to affordable, high quality medicines. The combination of Allergan and Actavis created one of the world’s top 10 pharmaceutical companies by revenue and a leader in a new industry model – Growth Pharma.
Actavis Biologics Ltd in Liverpool, becomes the Centre of Excellence for Biologics Drug Substance Development – increasing its product portfolio into branded and biosimilar products whilst widening patient access to best-in-class products. The Liverpool team are currently recruiting passionate and committed world class scientists, engineers and specialists with relevant skills and experience in biopharmaceuticals.